Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan
NCT06052800
·
clinicaltrials.gov ↗
ACTIVE_NOT_RECRUITING
Status
78
Enrollment
INDUSTRY
Sponsor class
Conditions
Fabry Disease
Sponsor
Sanofi